Overview

Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes

Status:
Terminated

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the antihypertensive and antiglycemic effects, as well as the safety and tolerability of TAK-491 (azilsartan medoxomil), once daily (QD), in stage 1 hypertensive, type 2 diabetes mellitus (T2DM) participants whose glycemic control was inadequate on metformin alone.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Azilsartan medoxomil
Metformin